Live Recordings (Sleep Medicine Trends 2026)-17 Sleep and Brain Health

Video Transcription

Video Summary

The speaker reviews evidence that sleep and neurologic disease influence each other, focusing on stroke, dementia, and Parkinson’s-spectrum disorders, and argues that routine sleep screening and treatment should be part of neurologic care.<br /><br />For stroke, obstructive sleep apnea (OSA) is an independent risk factor and is highly prevalent after stroke/TIA (often moderate–severe). Proposed mechanisms include intermittent hypoxemia, sympathetic activation and blood-pressure surges, arrhythmias (notably atrial fibrillation), inflammation, hypercoagulability, metabolic dysregulation, atherosclerosis, and possibly patent foramen ovale–related shunting. Despite this, few stroke patients report discussing sleep with their neurologist. Inpatient pulse oximetry can help screen but has variable accuracy and potential bias by skin tone and other factors; in-lab PSG remains ideal though access is difficult. CPAP can meaningfully reduce blood pressure and may reduce recurrent stroke/mortality when adhered to, but many trials were limited by late intervention and poor adherence; better-designed trials and alternative OSA therapies are needed.<br /><br />For dementia, abnormal sleep—especially disrupted slow-wave sleep—may precede dementia by years and relates to amyloid/tau accumulation and impaired glymphatic clearance. Observational data suggest PAP adherence lowers incident dementia risk; DORAs may reduce tau phosphorylation.<br /><br />For Parkinson’s disease, REM sleep behavior disorder (RBD) is a key prodrome with substantial long-term conversion risk to synucleinopathies. Management prioritizes safety plus melatonin/clonazepam; emerging biomarkers (smell testing, DAT scans, tissue biopsy, genetics) and new trials aim at earlier detection and neuroprotection.

Keywords

sleep screening in neurology

obstructive sleep apnea and stroke risk

CPAP adherence and recurrent stroke prevention

pulse oximetry vs polysomnography for OSA diagnosis

slow-wave sleep disruption and dementia biomarkers

amyloid tau accumulation and glymphatic clearance

dual orexin receptor antagonists (DORAs) and tau phosphorylation

REM sleep behavior disorder prodrome of Parkinson’s/synucleinopathies